Adverse effects of risperidone and haloperidol treatment in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 2, 2004, Pages 285-290

  Yen, Yung Chieh ^a,b   Lung, For Wey ^a   Chong, Mian Yoon ^c  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b Calo Psychiatric Center   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Extrapyramidal symptom rating scale; Haloperidol; Pisperidone; Positive and negative syndrome scale; Prolactin; UKU side effect rating scale

Indexed keywords

ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; HYPNOTIC AGENT; LAXATIVE; LORAZEPAM; NEUROLEPTIC AGENT; OXAZEPAM; PROLACTIN; RISPERIDONE; TEMAZEPAM; TRIHEXYPHENIDYL;

ACCOMMODATION PARALYSIS; ADULT; AKATHISIA; AKINESIA; AMENORRHEA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPOKINESIA; HYPOSALIVATION; LABORATORY TEST; LIBIDO DISORDER; MALE; MICTURITION DISORDER; MUSCLE RIGIDITY; NEGATIVE SYNDROME; PARKINSONISM; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TREMOR; VAGINAL DRYNESS;

EID: 1642482348     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.10.006     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorder. (DSM-III-R) 3rd rev. ed. 1987;American Psychiatric Press, Washington, DC.
2. Borison R.L., Parthiraja A., Diamond B.I., Meibach R.C. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol. Bull. 28:1992;213-218.
3. Breier A.F., Malhorta A.K., Su T.-P., Pinals D.A., Elam I., Adler C.M., Lafargue R.T., Clifton A., Pickar D. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry. 156:1999;294-298.
4. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
5. Carman J., Peuskens J., Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int. Clin. Psychopharmacol. 10:1995;207-213.
6. Chen Y.C., Ku C.S. Instruction Manual for the Structure Clinical Interview for DSM-III-R (SCID) in Chinese version. 1993;Kaohsiung Medical College, Kaohsiung.
7. Cheng J.J., Ho H., Chang C.J., Lan S.Y., Hwu H.G. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Taiwan J. Psychiatry. 10:1996;251-258.
8. Chouinard G., Ross-Chouinard A., Annable L., Jones B.D. The extrapyramidal symptom rating scale. (abstract) Can. J. Neurol. Sci. 7:1980;233.
9. Chouinard G., Jones B., Remington G., Bloom D., Addington D., Mac Ewan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
10. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J., Heylen S. Risperidone versus haloperidol in the treatment of chronic schizophrenia inpatients: a multicenter double-blind comparative study. Acta Psychiatr. Scand. 85:1992;295-305.
11. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 60:2003;553-564.
12. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1- and D2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
13. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 321:2000;1371-1376.
14. Hall H., Halldin C., Nyberg S., Farde L., Sedvall G. Effects of clozapine and risperidone on 5-HT and D2-dopamine receptor binding in the post-mortem human brain: an autoradiographic study. Eur. Neuropsychopharmacol. 5:1995;19-25.
15. 2 antagonistic properties. J. Pharm. Exp. Ther. 244:1988;685-693.
16. Jibson M.D., Tandon R. New atypical antipsychotic medications. J. Psychiatr. Res. 32:1998;215-228.
17. 2 occupancy, clinical responses, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157:2000;514-520.
18. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndromes Scale (PANSS) for schizophrenia. Schizophr. Bull. 12:1987;261-276.
19. Kay S.R., Olper L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS). Rating manual. Social and behavior document. 1987;San Rafael, California.
20. Kleinberg D.L., Davis J.M., De Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19:1999;57-61.
21. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 361:2003;1581-1589.
22. Leysen J.E., Janssen P.M., Megens A.A., Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, pharmacologic activity. J. Clin. Psychiatry. 55:1994;5-12. (supplement).
23. Lingjarde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 334(Suppl.):1987;1-100.
24. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
25. Mesotten F., Suy E., Pietquin M., Burton P., Hylens S., Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology. 99:1989;445-449.
26. Nyberg S., Nordstrom A.L., Halldin C., Farde L. Positron emission tomography studies on D2 dopamine receptor occupancy and antipsychotic drug plasma levels in man. Int. Clin. Psychopharmacol. 10(suppl. 3):1995;81-85.
27. 2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry. 156:1999;869-875.
28. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national multi-centre, double blind, parallel groups study versus haloperidol. Br. J. Psychiatry. 166:1995;712-726.
29. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
30. Seeman P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7:1992;261-284.
31. World Medical Association Declaration of Helsinki recommendation guiding physicians in biomedicalresearch involving human subjects. 18th World Medical Assembly, Helsinki, Finland. 1964.
32. World Medical Association Declaration of Tokyo guidelines for medical doctors concerning torture and other cruel, inhuman or degrading treatment or punishment in relation to detention and imprisonment. 29th World Medical Assembly, Tokyo, Japan. 1975.
33. World Medical Association Declaration of Venice on terminal illness. 35th World Medical Assembly, Venice, Italy. 1983.
34. World Medical Association Declaration of Hong Kong on the abuse of the elderly. 41st World Medical Assembly, Hong Kong. 1989.